Mercaptopurine Suspension
NDC Package 0054-0879-49

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Mercaptopurine suspension is a medication used to treat a certain type of cancer (acute lymphocytic leukemia). This formulation utilizes a suspension delivery system. Marketed by Hikma Pharmaceuticals Usa Inc., this product is identified by NDC 0054-0879 and is authorized under FDA application ANDA216418.

Identification & Billing

NDC Package Code
0054-0879-49
Package Description
1 BOTTLE, GLASS in 1 CARTON / 100 mL in 1 BOTTLE, GLASS
Product Code
0054-0879
11-Digit Billing Format
00054087949
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Mercaptopurine
Non-Proprietary Name
Mercaptopurine
Substance Name
Mercaptopurine
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
MERCAPTOPURINE 20 mg/mL
Pharmacologic Class
Usage Information
This medication is used to treat a certain type of cancer (acute lymphocytic leukemia). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. Talk to the doctor about the risks and benefits of mercaptopurine, especially when used in children and young adults.

Regulatory & Marketing

Labeler Name
Hikma Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216418
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-16-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0054-0879-49 identifies a specific commercial package of 1 bottle, glass in 1 carton / 100 ml in 1 bottle, glass of Mercaptopurine, a human prescription drug labeled by Hikma Pharmaceuticals Usa Inc.. This suspension is formulated for oral use and contains mercaptopurine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on June 16, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat a certain type of cancer (acute lymphocytic leukemia). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. Talk to the doctor about the risks and benefits of mercaptopurine, especially when used in children and young adults.

How is this Hikma Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00054087949. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0054-0879-49
11-Digit CMS (5-4-2)
00054-0879-49

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.